ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Achilles Therapeutics raises $120 million for T-cell therapy

by Ryan Cross
September 6, 2019 | APPEARED IN VOLUME 97, ISSUE 35

 

Achilles Therapeutics, a biotech start-up based in Stevenage, England, has raised about $120 million in series B financing to begin testing its personalized T-cell therapies in humans this year. Achilles is developing a method to isolate a class of T cells called tumor infiltrating lymphocytes (TILs) from a person’s tumors and enlarge a subset of those TILs that target specific mutations shared by multiple tumors in the individual. The firm will test the procedure as a way to use a patient’s own cells to treat lung cancer and melanoma.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment